Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy

Authors: V Drageset, JM Nesland, B Erikstein, E Skovlund, H Sommer, G Anker, E Wist, S Lundgren, J Bergh, G Kvalheim

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

The present study aimed to investigate the clinical relevance of minimal residual cancer in breast cancer patients before and after high-dose adjuvant chemotherapy with or without progenitor stem cell support. …
Literature
1.
Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, et al: Tailored fluorouracil, epirubicin, and cyclophos-phamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000, 356: 1384-1391. 10.1016/S0140-6736(00)02841-5.CrossRefPubMed
Metadata
Title
Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
Authors
V Drageset
JM Nesland
B Erikstein
E Skovlund
H Sommer
G Anker
E Wist
S Lundgren
J Bergh
G Kvalheim
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1185

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Poster Presentation

Immortalization-associated gene signature in breast cancer

Poster Presentation

Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)

Oral Presentation

Genomic analysis of human breast cancer in families and populations

Oral Presentation

ERβ in normal and malignant breast

Poster Presentation

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families

Oral Presentation

Stem cells in human breast development and cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits